David Liu (courtesy Broad Institute)

They’re go­ing for it: David Liu’s pre­clin­i­cal biotech shoots for a (maybe $200M) IPO

Can a pre­clin­i­cal biotech with grand am­bi­tions, a star sci­en­tif­ic founder and en­thu­si­as­tic back­ers with deep pock­ets fly a big IPO against the gale force head­winds we’ve seen this year?

In this econ­o­my?

The peo­ple at Prime Med­i­cine, which bills it­self as a CRISPR 3.0 play, aim to find out if they can buck the trend — which has re­lent­ed enough to al­low for one up­sized biotech IPO to get through — and pos­si­bly help pry open a win­dow that was slammed shut at the be­gin­ning of the year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.